An FDA panel unanimously supported the approval of a long-acting, injectable form of Eli Lilly & Co.’s Zyprexa (olanzapine) drug for the treatment of schizophrenia patients. The panel of outside medical experts said the injectable formulation was “acceptably safe” for stable patients or those suffering from acute attacks. The rare risk of patients experiencing excessive sedation or even coma after the administration of the injection is acceptable, considering the effectiveness of the drug. All patients recovered fully and the use of the drug has been continued for most of them. Zyprexa is currently approved in the oral and short-acting injectable forms.